Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries

View ORCID ProfileNiklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, View ORCID ProfileEero Poukka, Lars Christian Lund, Christian Holm Hansen, Mia Aakjær, Jesper Kjær, Catherine Cohet, Mathijs Goossens, Morten Andersen, Jesper Hallas, Hinta Meijerink, Rickard Ljung, Anders Hviid
doi: https://doi.org/10.1101/2022.11.24.22282651
Niklas Worm Andersson
1Department of Epidemiology Research, Staten Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Niklas Worm Andersson
  • For correspondence: nian@ssi.dk
Emilia Myrup Thiesson
1Department of Epidemiology Research, Staten Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrike Baum
2Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicklas Pihlström
3Division of Licensing, Swedish Medical Products Agency, Dag Hammarskjölds väg 42, 751 03 Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jostein Starrfelt
4Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Lovisenberggata 8, 0456 Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristýna Faksová
1Department of Epidemiology Research, Staten Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eero Poukka
2Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland
5Department of Public Health, Faculty of Medicine, University of Helsinki, Yliopistonkatu 4, 00100 Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eero Poukka
Lars Christian Lund
6Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, Faculty of Health Sciences, University of Southern Denmark, J. B. Winsløwsvej 19,2, 5000 Odense M, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Holm Hansen
7Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mia Aakjær
8Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen Ø, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesper Kjær
9Data Analytics Centre, Danish Medicines Agency, Axel Heides Gade 1, 2300 Copenhagen S, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Cohet
10European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathijs Goossens
10European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morten Andersen
8Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen Ø, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesper Hallas
6Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, Faculty of Health Sciences, University of Southern Denmark, J. B. Winsløwsvej 19,2, 5000 Odense M, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hinta Meijerink
11Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Lovisenberggata 8, 0456 Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rickard Ljung
12Division of Use and Information, Swedish Medical Products Agency, Dag Hammarskjölds väg 42, 751 03 Uppsala, Sweden
13Institute of Environmental Medicine, Karolinska Institutet, Nobels väg 13, 171 77 Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anders Hviid
1Department of Epidemiology Research, Staten Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
8Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen Ø, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective To investigate the effectiveness of heterologous booster schedules with AZD1222 (Oxford-AstraZeneca, referred to as AZD), BNT162b2 (Pfizer-BioNTech, BNT), and mRNA-1273 (Moderna, MOD) vaccines compared with primary schedules and with homologous mRNA-vaccine booster schedules during a period of omicron predominance.

Design Population-based cohort analyses.

Setting Denmark, Finland, Norway, and Sweden, 27 December 2020 to 28 February 2022.

Participants Adults that had received at least a primary vaccination schedule (ie, two doses) of the AZD, BNT, and/or MOD vaccines during the study period.

Main outcome measures Using the Kaplan-Meier estimator, we compared country-specific risks of SARS-CoV-2 infection and severe COVID-19 outcomes in heterologous booster vaccinated with primary schedule vaccinated (matched analyses) and homologous booster vaccinated (weighted analyses) since emergence of omicron.

Results Heterologous booster schedules improved protection against all outcomes compared with primary schedules, with the largest and most robust effects observed for severe COVID-19. Risk differences for documented infection ranged from -22.4% to -3.1% (comparative vaccine effectiveness [CVE] 9.7% to 60.9%; >63.2% for COVID-19 hospitalisation) across countries for AZD1BNT2BNT3 (AZD as primary dose followed by two doses of BNT) vs AZD1BNT2 and -22.2% to -3.2% (CVE 37.4% to 67.8%; >34.6% for hospitalisation) for BNT1BNT2MOD3 vs BNT1BNT2, the two most common heterologous booster schedules. Heterologous- and homologous booster schedules had comparable effectiveness. Risk differences of documented infection ranged from -0.4% to 4.4% (CVE -20.0% to 2.4%) for AZD1BNT2BNT3 vs BNT1BNT2BNT3 and -19.8% to 1.7% (CVE -14.6% to 53.8%) for BNT1BNT2MOD3 vs BNT1BNT2BNT3; for most comparisons, risk differences for severe COVID-19 outcomes were smaller than 1 per 1000 vaccinated. Previous infection followed by a booster dose conferred the greatest protection.

Conclusion Heterologous booster vaccine schedules are associated with an increased protection against omicron-related COVID-19 outcomes that is comparable to that afforded by homologous booster schedules.

Competing Interest Statement

LL reports participation in research projects funded by Menarini Pharmaceuticals and LEO Pharma with funds paid to his institution and receiving personal fees for teaching epidemiological methods related to COVID-19 research from Atrium, the Danish association of the pharmaceutical industry; all outside this submitted work. Man reports previous participation in research projects funded by Pfizer, Janssen, AstraZeneca, H Lundbeck, and Mertz, and Novartis with grants paid to the institution (Karolinska Institutet; no personal fees); MAn reports having received personal fees for teaching from Atrium and his institution, Pharmacovigilance Research Center, has been supported by a grant from the Novo Nordisk Foundation (NNF15SA0018404) to the University of Copenhagen; all outside this submitted work. JH reports participation in regulator-mandated phase IV-studies funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, and LEO Pharma with funds paid to the his institution; all outside this submitted work. RL reports receiving grants from Sanofi Aventis paid to his institution and receiving personal fees from Pfizer; all outside the submitted work. All other authors declare not competing interest.

Funding Statement

This research was supported by the European Medicines Agency.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Danish study was performed as a surveillance study as part of the governmental institution Statens Serum Institut's (SSI) advisory tasks for the Danish Ministry of Health. SSI's purpose is to monitor and fight the spread of disease in accordance with section 222 of the Danish Health Act. According to Danish law, national surveillance activities conducted by SSI do not require approval from an ethics committee. It was approved by the Danish Governmental law firm and SSI's compliance department that the study is fully compliant with all legal, ethical and IT-security requirements and there are no further approval procedures regarding such studies. For the Finnish study, by Finnish law, the Finnish Institute for Health and Welfare (THL) is the national expert institution to carry out surveillance on the impact of vaccinations in Finland (Communicable Diseases Act, https://www.finlex.fi/en/laki/kaannokset/2016/en20161227.pdf). Neither specific ethical approval (a waiver of ethical approval was received from Professor Mika Salminen, Director of the Department for Health Security Finnish Institute for Health and Welfare) of this study nor informed consent from the participants was needed. The Norwegian study was approved by the Norwegian Regional Committee for Health Research Ethics South East (REK Soer-Oest A, ref 122745), and has conformed to the principles embodied in the Declaration of Helsinki. The emergency preparedness register was established according to the Health Preparedness Act paragraph 2-4. Consent to participate was not applicable as this is a register-based study. The Swedish study is approved by the Swedish Ethical Review Authority (2020-06859, 2021-02186) and has conformed to the principles embodied in the Declaration of Helsinki. Consent to participate is not applicable as this is a register-based study. Due to the nature of this research, there was no involvement of patients or members of the public in the design or reporting of this study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

No additional data available. Owing to data privacy regulations in each country, the raw data cannot be shared.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 29, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, Eero Poukka, Lars Christian Lund, Christian Holm Hansen, Mia Aakjær, Jesper Kjær, Catherine Cohet, Mathijs Goossens, Morten Andersen, Jesper Hallas, Hinta Meijerink, Rickard Ljung, Anders Hviid
medRxiv 2022.11.24.22282651; doi: https://doi.org/10.1101/2022.11.24.22282651
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, Eero Poukka, Lars Christian Lund, Christian Holm Hansen, Mia Aakjær, Jesper Kjær, Catherine Cohet, Mathijs Goossens, Morten Andersen, Jesper Hallas, Hinta Meijerink, Rickard Ljung, Anders Hviid
medRxiv 2022.11.24.22282651; doi: https://doi.org/10.1101/2022.11.24.22282651

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1238)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10021)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (752)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2280)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (536)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (157)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4833)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (491)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)